$4.43
1.14% today
NYSE, Sep 12, 05:50 pm CET
ISIN
US05380C1027
Symbol
RCEL

AVITA Therapeutics Stock price

$4.38
-0.43 8.94% 1M
-3.99 47.67% 6M
-8.42 65.78% YTD
-5.19 54.23% 1Y
-1.82 29.35% 3Y
-21.83 83.29% 5Y
-0.72 14.12% 10Y
-20.62 82.48% 20Y
NYSE, Closing price Thu, Sep 11 2025
+0.21 5.04%
ISIN
US05380C1027
Symbol
RCEL
Industry

Key metrics

Basic
Market capitalization
$116.6m
Enterprise Value
$143.1m
Net debt
$26.5m
Cash
$15.7m
Shares outstanding
26.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.6 | 1.4
EV/Sales
1.9 | 1.7
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
5.6%
Return on Equity
-1,374.3%
ROCE
-4,110.2%
ROIC
612.5%
Debt/Equity
-3.3
Financials (TTM | estimate)
Revenue
$74.9m | $82.4m
EBITDA
$185.5m | $-23.4m
EBIT
$183.7m | $-36.8m
Net Income
$-51.6m | $-21.6m
Free Cash Flow
$-42.0m
Growth (TTM | estimate)
Revenue
38.3% | 28.2%
EBITDA
448.5% | 57.3%
EBIT
440.2% | 34.3%
Net Income
-3.5% | 65.0%
Free Cash Flow
27.8%
Margin (TTM | estimate)
Gross
392.2%
EBITDA
247.7% | -28.4%
EBIT
245.4%
Net
-68.9% | -26.3%
Free Cash Flow
-56.0%
More
EPS
$-2.0
FCF per Share
$-1.6
Short interest
20.1%
Employees
260
Rev per Employee
$250.0k
Show more

Is AVITA Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

AVITA Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a AVITA Therapeutics forecast:

10x Buy
77%
1x Hold
8%
2x Sell
15%

Analyst Opinions

13 Analysts have issued a AVITA Therapeutics forecast:

Buy
77%
Hold
8%
Sell
15%

Financial data from AVITA Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
75 75
38% 38%
100%
- Direct Costs -219 -219
3,164% 3,164%
-292%
294 294
525% 525%
392%
- Selling and Administrative Expenses 88 88
10% 10%
118%
- Research and Development Expense 22 22
2% 2%
29%
186 186
448% 448%
248%
- Depreciation and Amortization 1.79 1.79
136% 136%
2%
EBIT (Operating Income) EBIT 184 184
440% 440%
245%
Net Profit -52 -52
3% 3%
-69%

In millions USD.

Don't miss a Thing! We will send you all news about AVITA Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AVITA Therapeutics Stock News

Neutral
GlobeNewsWire
3 days ago
Investors can contact the law firm at no cost to learn more about recovering their losses
Neutral
Business Wire
3 days ago
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of AVITA Medical, Inc. (“AVITA” or the “Company”) (NASDAQ:RCEL) investors concerning the Company's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On August 7, 2025, AVITA released its second quar...
Neutral
Seeking Alpha
4 days ago
AVITA Medical, Inc. (NASDAQ:RCEL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:05 PM EDT Company Participants James Corbett - CEO, President & Executive Director Presentation Unknown Analyst Okay. Thank you, everybody, for joining us.
More AVITA Therapeutics News

Company Profile

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.

Head office United States
CEO James Corbett
Employees 260
Founded 1992
Website www.avitamedical.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today